Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids: A protocol for systematic review and meta-analysis

BACKGROUND: Infliximab and cyclosporine are two main therapies in treating acute severe ulcerative colitis (ASUC), our objective is to assess the effectiveness and safety of cyclosporine (CSA) versus infliximab (IFX) as rescue agents in patients with steroid-refractory ulcerative colitis (UC). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Dongjie, Yang, Zhen, Zhao, Chen, Yao, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203526/
https://www.ncbi.nlm.nih.gov/pubmed/30313056
http://dx.doi.org/10.1097/MD.0000000000012657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203526/
https://www.ncbi.nlm.nih.gov/pubmed/30313056
http://dx.doi.org/10.1097/MD.0000000000012657

Ejemplares similares